Long-Term BMD Gain With Prolia Shown in 10-Year Study Data

Amgen announced results from a 7-year, single-arm, open-label extension of the 3-year randomized, double-blind, placebo-controlled, multi-center, international Phase 3 FREEDOM Study.

New Findings for Plaque Psoriasis Tx Otezla Presented

Celgene announced that new findings from its ongoing Phase 3 LIBERATE trial evaluating Otezla (apremilast) in patients with moderate to severe plaque psoriasis were presented at the 24th European Academy of Dermatology and Venereology (EADV) Congress.

Lithium Appears Safe, Effective Tx for Children

Lithium was superior to placebo in reducing manic symptom in pediatric patients treated for bipolar I disorder (BP-I) and was generally well-tolerated, according to a new study in Pediatrics.

First-of-Its-Kind Pharmacogenetic Test Could Predict Medication Response

DNA4Life announced the launch of their Pharmacogenetic Report, a genetic test that can analyze a patient's DNA to predict their response commonly prescribed medications across therapeutic classes.

Bioresorbable Vascular Scaffold Deemed Noninferior

Noninferior to treatment with everolimus-eluting cobalt-chromium stent for coronary artery disease

Advanced-Stage Breast CA More Likely in Certain Racial Groups

African-American, white Hispanic women more likely to receive non-guideline-concordant treatment

Contamination of Skin, Clothing of Healthcare Workers Common

Contamination of skin or clothing common in personnel removing personal protective equipment

Which 'Choosing Wisely' Recs Have Made the Most Impact?

Declines in two of seven recommendations: imaging for headache, cardiac imaging for low-risk patients

HIV Tx May Also Offer Protection Against Hepatitis B

Risk factors for incident HBV include younger age, more than one sexual partner, HIV infection

In Controlled T2DM, Wine at Dinner Can Add Heart Benefits

Findings in patients with controlled diabetes adding alcohol nightly to Mediterranean diet